BIIB - Biogen Inc

https://www.biogen.com

Hold Momentum: Bearish

Recent News

Will AbbVie's Neuroscience Portfolio Continue to Aid Top-line Growth?

Zacks Commentary • 1 week, 4 days ago • score: -0.18

ABBV's expanding neuroscience portfolio, led by Botox, Vraylar and new launches like Vyalev, continues to fuel top-line growth.

Neutral

C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration

GlobeNewswire • 1 week, 4 days ago • score: 0.08

Development Candidate Targeting IRAK4 Now Progressing Toward Clinical Development Development Candidate Targeting IRAK4 Now Progressing Toward Clinical Development ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.

52W High

$204.18

52W Low

$110.04

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

0.11

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

13.46

Forward P/E (<15 better)

8.78

EV/EBITDA (<8 favorable)

8.75

EV/Revenue (<3 favorable)

2.45

P/S (TTM) (<3 favorable)

2.06

P/B (<3 favorable)

1.17

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

0.15%

Institutions (25–75% balanced)

92.59%

Shares Outstanding

146,615,000

Float

146,226,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

9,997,000,000

Gross Profit (TTM)

7,556,200,000

EPS (TTM)

10.45

Profit Margin (>10% good)

0.15%

Operating Margin (TTM) (higher better)

0.35%

ROE (TTM) (>15% strong)

0.09%

EPS YoY (Quarterly) (>10% good)

0.08

Revenue YoY (Quarterly) (>8% good)

0.07

Momentum

Bearish momentum

Value

3.8933

3.8386

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025